Connect Sign In
This Newborn Screening Awareness Month, learn how updated ARUP Consult® topics support clinicians with evidence-based recommendations for diagnostic testing, monitoring, and genetic testing.
September is Newborn Screening (NBS) Awareness Month, which highlights the vital role NBS plays in identifying serious health conditions early in life. According to the National Institutes of Health, approximately four million infants are screened annually in the United States for treatable disorders, including rare genetic, hormone-related, and metabolic conditions that can cause serious health problems.
NBS is a state-based public health program designed to support early detection and intervention. These efforts help reduce morbidity and mortality associated with a variety of inherited and congenital disorders. Although screening panels vary by state, many include conditions on the Recommended Uniform Screening Panel, such as:
While NBS identifies infants who may be at risk, additional laboratory testing is often required to confirm a diagnosis, guide treatment decisions, and support ongoing patient management. To support clinicians, ARUP Consult® has recently updated topics on the conditions listed above.
The evidence-based topics incorporate current guidelines and provide recommendations on diagnostic testing, follow-up evaluation, monitoring, and genetic testing. ARUP Laboratories’ medical directors, who also serve on the faculty of the Spencer Fox Eccles School of Medicine at the University of Utah, contribute to and review ARUP Consult, which offers guidance to help care teams select the right test at the right time.
Users can subscribe for monthly updates and new content additions on the ARUP Consult website. ARUP also welcomes suggestions and comments via the Consult Feedback page.
Learn more about newborn screening by state.
Bonnie Stray, bonnie.stray@aruplab.com
